Meeting
2022 ASCO Annual Meeting
Trial in progress: A phase I trial of dual EZH 1/2 inhibitor valemetostat tosylate (DS-3201b) in pediatric, adolescent, and young adult patients with malignant solid tumors.
Authors
Ayumu Arakawa
Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan
Ayumu Arakawa , Hitoshi Ozawa , Akihiro Hirakawa , Ryo Sadachi , Yukari Hoshina , Sawako Tomatsuri , Yoshimasa Saito , Reiko Makihara Ando , Keita Terashima , Kenichi Nakamura , Chitose Ogawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS10059)
DOI
10.1200/JCO.2022.40.16_suppl.TPS10059
Abstract #
TPS10059
Poster Bd #
272b
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
A phase 1, multi-center, safety, feasibility, and preliminary efficacy study evaluating a single dose of UNO101 in relapsed or refractory, unresectable, primary, or metastatic cutaneous and subcutaneous malignancies.
First Author: Frederick M. Dirbas
Poster
2022 ASCO Annual Meeting
SHR2554, an enhancer of zeste homolog 2 (EZH2) inhibitor, in relapsed or refractory (r/r) mature lymphoid neoplasms: A first-in-human phase 1 study.
First Author: Yuqin Song
Poster
2024 ASCO Annual Meeting
Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors.
First Author: Gerald Steven Falchook
Poster
2024 ASCO Annual Meeting
TAZNI: A phase I/II combination trial of tazemetostat with nivolumab and ipilimumab for children with INI1-negative or SMARCA4-deficient tumors.
First Author: Joanna S. Yi